Reduction of Mevalonate Pyrophosphate Decarboxylase in Mouse Melanoma Cells Treated with δ-Tocotrienol Is Not Associated with Reduction of Cholesterol Content or Release of Lysosomes and Melanosomes
-
- Michihara Akihiro
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University
-
- Shimatani Mai
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University
-
- Morita Sachiyo
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University
-
- Akasaki Kenji
- Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University
書誌事項
- タイトル別名
-
- Reduction of Mevalonate Pyrophosphate Decarboxylase in Mouse Melanoma Cells Treated with δ-Tocotrienol Is Not Associated with Reduction of Cholesterol Content or Release of Lysosomes and Melanosomes
- Reduction of mevalonate pyrophosphate decarboxylase in mouse melanoma cells treated with デルタ tocotrienol is not associated with reduction of cholesterol content or release of lysosomes and melanosomes
この論文をさがす
抄録
We previously reported that a decrease in the melanin content of mouse melanoma cells (B16 cells) treated with δ-tocotrienol was the result of a decrease in the level of tyrosinase activity and protein. Use of δ-tocotrienol as a whitening agent, may therefore have side effects. In the present study, we examined whether δ-tocotrienol caused side effects (the release of lysosomes from and a decrease in the cholesterol content of cells). We also examined the release of melanosomes (lysosome-related organella). Neither of lysosomes nor melanosomes were released from cells treated with δ-tocotrienol, since β-glucuronidase (melanosomal and lysosomal enzyme) activity, melanin content (melanosomal marker), and tyrosinase (melanosomal enzyme) activity did not increase in the cell culture medium. Although mevalonate pyrophosphate decarboxylase (MPD; an enzyme of cholesterol biosynthesis) was significantly reduced in the cells treated with δ-tocotrienol, cholesterol content was not. Thus, δ-tocotrienol might be useful as a therapeutic or preventive drug for hyperpigmentation and as a component of whitening and/or lightening cosmetics not causing severe side effect (reduction of cholesterol content and release of lysosomes/melanosomes), although δ-tocotrienol cause a decrease of MPD.
収録刊行物
-
- JOURNAL OF HEALTH SCIENCE
-
JOURNAL OF HEALTH SCIENCE 56 (3), 355-360, 2010
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204499380096
-
- NII論文ID
- 130000254737
-
- NII書誌ID
- AA11316464
-
- ISSN
- 13475207
- 13449702
-
- NDL書誌ID
- 10688773
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可